Intrapleural Fibrinolytics- A review

Dr. Girish L. Dandagi, MBBS, MD*

*Associate Professor, Department of TB and Respiratory Medicine, Belgaum Institute of Medical Sciences,
Belgaum, Karnataka, India.

Abstract: Fibrinolytic therapy can be used for complicated pleural effusions or empyema without the need for operative intervention. Intrapleural administration of Fibrinolytics prevents intrapleural organization and loculation. However, the success of this therapy has provided a strong rationale for the continued utilization of fibrinolytic therapy to address extensive intrapleural loculation and lung entrapment. Over the last several years; additional studies were done to explore the efficacy and safety of intrapleurally administered Fibrinolytics.

Key words: Streptokinase, urokinase, empyema, Fibrinolytics

I Introduction

The fibrin strands within pleural exudates initiate intrapleural loculation in the form of fibrin. The clearance of this fibrin by intrapleural administration of Fibrinolytics prevents intrapleural organization and loculation. Beginning in the 1940s, Dr Sherry1 and Tillett et al2 demonstrated that preparations of streptokinase or streptodornase could be used to resolve pleural loculations attributable to parapneumonic effusions or hemothoraces3. However, the success of this therapy has provided a strong rationale for the continued utilization of fibrinolytic therapy to address extensive intrapleural loculation and lung entrapment. Over the last several years; additional studies were done to explore the efficacy and safety of intrapleurally administered Fibrinolytics. The current article reviews about these intrapleural agents in detail.

Discussion

Various agents used as Fibrinolytics like streptokinase urokinase and others are discussed below in detail. Streptokinase has been associated with febrile reactions but has been generally well tolerated, as reported in a number of studies. Intrapleural streptokinase, as commonly used for intrapleural administration, does not induce systemic fibrinolysis and is relatively free of hemorrhagic risk.4 5 Intrapleural urokinase has likewise been reported to be well-tolerated6. The cost of intrapleurally administered agents has favored streptokinase as reported in prior studies, but urokinase has been reported to be cost effective. Streptokinase is available in a 750,000 IU dose and 15 lakh IU dose. Urokinase is now available in 250,000 IU / 5,000,000 IU / 7,50,000 IU / 10,00,000 IU dose. Tissue plasminogen activator (tPA) is available in 50-mg vials7.

Fibrinolytic Agents Used for Intrapleural Applications.

1. Streptokinase: Single-chain glycoprotein of molecular weight 40,000–50,000 kDa. Not an enzyme which generates plasmin through complex formation with and catalysis of plasminogen. Rapid half-life; cleared within minutes. It can induce antistreptokinase antibodies and a least expensive fibrinolysin8.

2. Urokinase plasminogen activator (uPA): Low-molecular-weight form which predominates in commercial preparations; molecular weight 33,000 kDa. Rapid plasma half-life; cleared within minutes. Directly activates plasminogen to form plasmin. Endogenous plasminogen activator that can be detected in pleural fluids and plasma.

3. Tissue plasminogen activator (tPA): Glycosylated protein of molecular weight 68,000 kDa. Rapid plasma half-life; cleared within minutes. Recombinant material is used therapeutically. Endogenous tPA detectable in pleural fluid and plasma9.

Overview of Clinical Trials of Intrapleural Fibrinolytic Therapy

In the 1970s, Bergh and colleagues1 revisited the use of streptokinase as an intervention to treat loculations associated with hemothoraxes or parapneumonic effusions. In this study thirty-eight patients with haemothorax or empyema, in whom conventional drainage treatment had proved ineffective were treated with streptokinase instillations. An increased yield of fluid was noted in all 30 of 38 cases, up to 1300 ml after one instillation. Re-expansion of the lung was observed radiologically in 30 cases. No serious complications occurred with streptokinase instillation.
Bouros and colleagues\(^9\) likewise found that urokinase was similarly well tolerated and effective after intrapleural instillation in patients in whom adequate drainage was not achieved with a single chest tube placed for complicated para pneumonic effusions or empyema’s. Clinical and radiologic improvement was noted in 19 of 20 patients, with an “excellent” radiologic response in 13 patients. In a follow-up uncontrolled trial, 50 patients with para pneumonic effusions or empyema and inadequate chest tube drainage were randomized, in a double-blind manner, to receive either urokinase or streptokinase by the same group. They found that streptokinase-treated patients were more prone to the development of febrile reactions, and that both agents appeared to decrease the need for surgical intervention\(^8\). In this trial, the fibrinolytics were given in 100 mL of normal saline, and a dwell time of 3 hours was used. The daily dose of streptokinase was 2,500,000 IU/dose, while that of uPA was 1,000,000 IU/dose, which are comparable to those used in other clinical trials. This group reported that only about 10% of patients failed to respond to administration of fibrinolytic agents over a 5-year period, but in such cases, video-assisted thoracoscopy was an effective follow-up option \(^11\).

In a multicenter, uncontrolled trial of 48 patients from Mexico, including those with empyema and hemothorax, intrapleural streptokinase was found to be effective in 92% of patients and obviated the need for surgical intervention\(^12\). In this study forty-eight patients were studied; there were 30 patients with empyemas, 14 with hemothorax, and 4 patients with malignant pleural effusions without lung trapping. Successful fibrinolysis was obtained in 44 patients, with complete resolution of the pleural collection and adequate radiologic and spirometric improvement. In three of four patients with multiloculated malignant hemothorax with high-yielding pleural drainage, Intrapleural Streptokinase treatment allowed successful lysis of loci and an adequate pleurodesis was achieved. Only four patients required surgical treatment.

The findings in a report from Estonia were likewise encouraging, in that\(^13\) 28 patients (aged 22 to 62 years) with multioccluded pleural effusions treated with intrapleural instillations of streptokinase after unsuccessful conventional chest tube drainage. Twenty-three pleural effusions were grossly purulent, others were loculated effusions with low pH. Treatment with streptokinase was started most commonly one day after chest tube placement. Once a day after clamping the chest tube streptokinase was administered intrapleurally for 10-15 minutes as a solution of 250,000 units in 100 mL normal saline. The tube remained clamped for 3 hours. Eleven patients experienced some adverse effects of streptokinase therapy, most frequently chest pain and elevation of body temperature in one case pleural effusion became hemorrhagic, and one patient had nasal bleeding.

In a study from a Veterans Administration hospital in the United States, favorable results were likewise observed in 18 of 26 patients treated with either streptokinase or urokinase for empyema, and the treatment was felt to again obviate the need for surgical intervention\(^14\). Twenty-six patients were treated. Sixty-two percent (16/26) had complete resolution (CR) of symptoms, near or complete normalization of chest radiographic findings, and required no surgery or empyema tubes. Bleeding occurred in a single patient (4%). There was no mortality associated with fibrinolytic use. Similar results were reported in a study of 54 patients with empyema’s or hemothoraces treated with intracavitary, trans catheter urokinase\(^15\).

In pediatric patients, intrapleural urokinase was likewise found to be effective in all 9 children age 6 or less with intrapleural loculations associated with complicated parapneumonic effusions\(^16\). In the aggregate, the results of several uncontrolled trials support the use of fibrinolytic therapy for intrapleural loculations. In this study nine children, ages 6 months to 6 years, with complicated parapneumonic effusions who received intrapleural urokinase after failing to respond to IV antibiotics and closed-tube thoracostomy drainage. Four subjects had additional thoroscopic adhesiolysis before intrapleural instillation of urokinase; 20,000 IU of diluted urokinase was instilled three times a day via the thoracostomy tube for 3 days. Among these eight subjects responded to 3 days of urokinase instillation, with increased thoracostomy tube drainage and clinical resolution of symptoms. The remaining subject responded to a second course of instillation. All subjects tolerated the procedure well. No bleeding, fever, anaphylaxis, or allergic reactions were noted. The coagulation parameters remained unchanged.

There are relatively few randomized, controlled clinical trials that address the use of intrapleural fibrinolytics to relieve intrapleural loculations. In one such trial, Davies and colleagues\(^17\) found that streptokinase facilitated pleural drainage and radiographic improvement of the intrapleural collections, which were due to empyema. In this trial, 24 patients were randomized and received either intrapleural saline or streptokinase daily over 3 days. Only patients in the control group required surgical intervention, and systemic fibrinolysis or bleeding did not occur in the streptokinase treated patients.

In another controlled trial of 31 consecutive patients with multiloculated effusions, urokinase instillation was found to be superior to saline administration\(^18\). Patients again received a course of treatment over 3 days. Clinical and radiographic improvement was seen in 13 of 15 patients treated with urokinase and only 4 of 16 in the saline-treated patients. Twelve patients in the control group were subsequently treated with uPA, and half of them then had resolution of intrapleural loculations. The authors concluded that intrapleural administration of uPA was effective in the treatment of multiloculated effusions.

www.iosrjournals.org 46 | Page
These results were confirmed in another controlled clinical trial from Turkey. In this study, Forty-nine patients with Para pneumonia empyema were randomly assigned to receive either intrapleural urokinase or normal saline treatment. The daily volume instilled through a chest tube was 100 ml in both groups. Urokinase (100,000 IU/day) was diluted in normal saline before instillation. The mean volume of drained fluid during the five-day treatment period was significantly greater in the urokinase group than in the control group. The subsequent decortication rate was 60% and 29.1%, respectively. The duration of hospitalization was also shorter in the urokinase group than in the saline group.

It has been observed by Dourous that intrapleural fibrinolytic at a daily dose of 1,00,00 IU for 3 days is safe and effective in improving chest-tube drainage and reducing the hospital stay of patients with empyema. This study showed that patients who received intrapleural fibrinolytics had a decreased need for hospitalization compared with patients who received saline intrapleurally. Also it was observed that intrapleural fibrinolytic treatment does not appear to alter systemic coagulation parameters. In fact, no clinical or statistically significant deviations of the hematologic parameters were observed.

II Conclusion

It can be concluded that routinely fibrinolytic therapy can be used for complicated pleural effusions or empyema without the need for operative intervention.

Reference:

Intrapleural Fibrinolytics- A review


